{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:23:53Z","timestamp":1793046233494,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":172,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Netherlands Organisation for Scientific Research","doi-asserted-by":"crossref","award":["NWO-VENI-863.12.005"],"award-info":[{"award-number":["NWO-VENI-863.12.005"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003246","name":"Netherlands Organisation for Scientific Research","doi-asserted-by":"crossref","award":["NWO-VENI-722.012.066"],"award-info":[{"award-number":["NWO-VENI-722.012.066"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003246","name":"Netherlands Organisation for Scientific Research","doi-asserted-by":"crossref","award":["NWO-VICI-91812628"],"award-info":[{"award-number":["NWO-VICI-91812628"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ERASysApp","award":["832.14.003"],"award-info":[{"award-number":["832.14.003"]}]},{"name":"European Union (Horizon 2020 Marie Sk\u0142odowska-Curie ETN \u2018ANTIVIRALS\u2019","award":["642434"],"award-info":[{"award-number":["642434"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.coviro.2017.03.009","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T15:46:42Z","timestamp":1492012002000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["Direct-acting antivirals and host-targeting strategies to combat enterovirus infections"],"prefix":"10.1016","volume":"24","author":[{"given":"Lisa","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyrhyoung","family":"Lyoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde M","family":"van der Schaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen RPM","family":"Strating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank JM","family":"van Kuppeveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2017.03.009_bib0005","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.meegid.2012.10.016","article-title":"Picornavirus and enterovirus diversity with associated human diseases","volume":"14","author":"Tapparel","year":"2013","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/978-1-4614-7651-1_2","article-title":"Picornavirus entry","volume":"790","author":"Bergelson","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/med.20125","article-title":"Selective inhibitors of picornavirus replication","volume":"28","author":"De Palma","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.coviro.2017.03.009_bib0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcp.2011.08.016","article-title":"Combating enterovirus replication: state-of-the-art on antiviral research","volume":"83","author":"Thibaut","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0025","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.3390\/v7082832","article-title":"Replication and inhibitors of enteroviruses and parechoviruses","volume":"7","author":"van der Linden","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2017.03.009_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jpids\/piv015","article-title":"A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis","volume":"5","author":"Abzug","year":"2016","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"10.1016\/j.coviro.2017.03.009_bib0035","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1128\/AAC.49.11.4492-4499.2005","article-title":"Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses","volume":"49","author":"Pevear","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0040","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1099\/vir.0.069773-0","article-title":"Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient","volume":"96","author":"Benschop","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.virol.2013.10.004","article-title":"Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance","volume":"448","author":"Basta","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2017.03.009_bib0050","doi-asserted-by":"crossref","first-page":"13524","DOI":"10.1128\/JVI.02094-12","article-title":"Infection and propagation of human rhinovirus C in human airway epithelial cells","volume":"86","author":"Hao","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.009_sbref0055","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1073\/pnas.1606595113","article-title":"Atomic structure of a rhinovirus C, a virus species linked to severe childhood asthma","volume":"113","author":"Liu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.03.009_bib0060","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1073\/pnas.1524498113","article-title":"Enterovirus D68 receptor requirements unveiled by haploid genetics","volume":"113","author":"Baggen","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.03.009_bib0065","doi-asserted-by":"crossref","first-page":"8865","DOI":"10.1038\/ncomms9865","article-title":"Sialic acid-dependent cell entry of human enterovirus D68","volume":"6","author":"Liu","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.coviro.2017.03.009_bib0070","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrmicro3346","article-title":"The sweet spot: defining virus-sialic acid interactions","volume":"12","author":"Stencel-Baerenwald","year":"2014","journal-title":"Nat. Rev. Micro."},{"key":"10.1016\/j.coviro.2017.03.009_bib0075","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/infdis\/jis622","article-title":"A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection","volume":"206","author":"Moss","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.009_bib0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.antiviral.2013.04.012","article-title":"The use of sialidase therapy for respiratory viral infections","volume":"98","author":"Nicholls","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.coviro.2017.03.009_bib0085","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.1128\/AAC.00766-15","article-title":"In vitro efficacy of antiviral compounds against enterovirus D68","volume":"59","author":"Rhoden","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0090","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1073\/pnas.96.20.11000","article-title":"Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes","volume":"96","author":"Matthews","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.03.009_bib0095","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/AAC.49.2.619-626.2005","article-title":"Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor","volume":"49","author":"Binford","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0166-3542(00)00106-6","article-title":"In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses","volume":"47","author":"Kaiser","year":"2000","journal-title":"Antiviral Res."},{"key":"10.1016\/j.coviro.2017.03.009_bib0105","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1128\/AAC.43.10.2444","article-title":"In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease","volume":"43","author":"Patick","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0110","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1128\/AAC.46.2.392-397.2002","article-title":"Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers","volume":"46","author":"Hsyu","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0115","first-page":"729","article-title":"Liquid chromatography\u2013mass spectrometry and liquid chromatography-NMR characterization of in vitro metabolites of a potent and irreversible peptidomimetic inhibitor of rhinovirus 3C protease","volume":"29","author":"Zhang","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.coviro.2017.03.009_bib0120","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1128\/AAC.47.12.3907-3916.2003","article-title":"Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers","volume":"47","author":"Hayden","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0125","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.49.6.2267-2275.2005","article-title":"In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease","volume":"49","author":"Patick","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0130","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1128\/JVI.01123-12","article-title":"3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0135","doi-asserted-by":"crossref","first-page":"33663","DOI":"10.1038\/srep33663","article-title":"Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease","volume":"6","author":"Tan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.coviro.2017.03.009_bib0140","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbagen.2016.03.017","article-title":"Fragment-wise design of inhibitors to 3C proteinase from enterovirus 71","volume":"1860","author":"Wu","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.coviro.2017.03.009_bib0145","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ejmech.2016.10.019","article-title":"Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening","volume":"124","author":"Ma","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.coviro.2017.03.009_bib0150","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.coviro.2017.03.009_bib0155","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1073\/pnas.1232294100","article-title":"A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity","volume":"100","author":"Pfeiffer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.03.009_bib0160","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2017.03.009_bib0165","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.009_bib0170","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1128\/JVI.01207-14","article-title":"Inhibition of enterovirus 71 by adenosine analog NITD008","volume":"88","author":"Deng","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.10.011","article-title":"Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses","volume":"124","author":"Kang","year":"2015","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.coviro.2017.03.009_bib0180","first-page":"45","article-title":"Cell-based high-throughput screening assay identifies 2\u2032,2\u2032-difluoro-2\u2032-deoxycytidine Gemcitabine as potential anti-poliovirus agent, ACS Infect","volume":"2017","author":"Zhang","year":"2016","journal-title":"Dis."},{"key":"10.1016\/j.coviro.2017.03.009_sbref0185","doi-asserted-by":"crossref","first-page":"e1004733","DOI":"10.1371\/journal.ppat.1004733","article-title":"The RNA template channel of the RNA-dependent RNA polymerase as a target for development of antiviral therapy of multiple genera within a virus family","volume":"11","author":"van der Linden","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.coviro.2017.03.009_bib0190","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.1128\/JVI.01756-16","article-title":"SUMO modification stabilizes enterovirus 71 polymerase 3D to facilitate viral replication","volume":"90","author":"Liu","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0195","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/AAC.02182-15","article-title":"Screening of a library of FDA-approved drugs identifies several enterovirus replication inhibitors that target viral protein 2C","volume":"60","author":"Ulferts","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0200","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/AAC.02084-12","article-title":"Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C","volume":"57","author":"Ulferts","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0205","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1128\/AAC.00983-12","article-title":"Fluoxetine is a potent inhibitor of coxsackievirus replication","volume":"56","author":"Zuo","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_sbref0210","doi-asserted-by":"crossref","first-page":"e1005067","DOI":"10.1371\/journal.ppat.1005067","article-title":"Human enterovirus nonstructural protein 2CATPase functions as both an RNA helicase and ATP-independent RNA chaperone","volume":"11","author":"Xia","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.coviro.2017.03.009_sbref0215","first-page":"64:94","article-title":"Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked Agammaglobulinemia","author":"Gofshteyn","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0220","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/MMBR.00012-14","article-title":"Picornavirus morphogenesis","volume":"78","author":"Jiang","year":"2014","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.coviro.2017.03.009_bib0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1101\/gad.1505307","article-title":"Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance","volume":"21","author":"Geller","year":"2007","journal-title":"Genes. Dev."},{"key":"10.1016\/j.coviro.2017.03.009_sbref0230","doi-asserted-by":"crossref","first-page":"e1004052","DOI":"10.1371\/journal.ppat.1004052","article-title":"An interaction between glutathione and the capsid is required for the morphogenesis of C-cluster enteroviruses","volume":"10","author":"Ma","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.coviro.2017.03.009_sbref0235","doi-asserted-by":"crossref","first-page":"e1004039","DOI":"10.1371\/journal.ppat.1004039","article-title":"Binding of glutathione to enterovirus capsids is essential for virion morphogenesis","volume":"10","author":"Thibaut","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.coviro.2017.03.009_bib0240","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1128\/JVI.02877-15","article-title":"A single amino acid substitution in poliovirus nonstructural protein 2CATPase causes conditional defects in encapsidation and uncoating","volume":"90","author":"Asare","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0245","doi-asserted-by":"crossref","first-page":"e1001066","DOI":"10.1371\/journal.ppat.1001066","article-title":"Direct interaction between two viral proteins, the nonstructural protein 2C and the capsid protein VP3, is required for enterovirus morphogenesis","volume":"6","author":"Liu","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.coviro.2017.03.009_bib0250","doi-asserted-by":"crossref","first-page":"9964","DOI":"10.1128\/JVI.00914-12","article-title":"Alanine scanning of poliovirus 2CATPase reveals new genetic evidence that capsid protein\/2CATPase interactions are essential for morphogenesis","volume":"86","author":"Wang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0255","doi-asserted-by":"crossref","first-page":"e77133","DOI":"10.1371\/journal.pone.0077133","article-title":"Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy","volume":"8","author":"Tsou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2017.03.009_bib0260","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.tim.2016.02.017","article-title":"Fat(al) attraction: picornaviruses usurp lipid transfer at membrane contact sites to create replication organelles","volume":"24","author":"van der Schaar","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.coviro.2017.03.009_sbref0265","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cell.2010.03.050","article-title":"Viral reorganization of the secretory pathway generates distinct organelles for RNA replication","volume":"141","author":"Hsu","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2017.03.009_bib0270","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1128\/AAC.01175-13","article-title":"A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIbeta","volume":"57","author":"van der Schaar","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0275","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1128\/JVI.02249-10","article-title":"Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity","volume":"85","author":"Arita","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0280","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.chom.2014.10.003","article-title":"Rhinovirus uses a phosphatidylinositol 4-phosphate\/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface","volume":"16","author":"Roulin","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2017.03.009_bib0285","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1128\/AAC.00946-12","article-title":"Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors","volume":"56","author":"Lamarche","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0290","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acsinfecdis.5b00122","article-title":"Mechanism of poliovirus resistance to host phosphatidylinositol-4 kinase III beta inhibitor","volume":"2","author":"Arita","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.009_bib0295","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/cr.2012.129","article-title":"Coxsackievirus mutants that can bypass host factor PI4KIIIbeta and the need for high levels of PI4P lipids for replication","volume":"22","author":"van der Schaar","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.coviro.2017.03.009_sbref0300","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2014.12.054","article-title":"Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein","volume":"10","author":"Strating","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.coviro.2017.03.009_bib0305","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.05108-14","article-title":"Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A","volume":"59","author":"Gao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.coviro.2017.03.009_bib0310","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.cell.2013.09.056","article-title":"A four-step cycle driven by PI(4)P hydrolysis directs sterol\/PI(4)P exchange by the ER-Golgi tether OSBP","volume":"155","author":"Mesmin","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2017.03.009_bib0315","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.02.013","article-title":"Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP","volume":"117","author":"Albulescu","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.coviro.2017.03.009_bib0320","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1128\/JVI.03546-12","article-title":"Oxysterol-binding protein family I is the target of minor enviroxime-like compounds","volume":"87","author":"Arita","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0325","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.antiviral.2017.01.008","article-title":"Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307","volume":"140","author":"Albulescu","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.coviro.2017.03.009_bib0330","doi-asserted-by":"crossref","first-page":"23110","DOI":"10.1038\/srep23110","article-title":"Therapeutic and prophylactic activity of itraconazole against human rhinovirus infection in a murine model","volume":"6","author":"Shim","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.coviro.2017.03.009_sbref0335","doi-asserted-by":"crossref","first-page":"e1004422","DOI":"10.1371\/journal.ppat.1004422","article-title":"Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator","volume":"10","author":"Qing","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.coviro.2017.03.009_bib0340","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/v5071684","article-title":"Cyclophilins as modulators of viral replication","volume":"5","author":"Frausto","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2017.03.009_bib0345","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.yjmcc.2012.03.004","article-title":"Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis","volume":"53","author":"Seizer","year":"2012","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.coviro.2017.03.009_bib0350","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1038\/ncomms6237","article-title":"Structural basis of IL-23 antagonism by an Alphabody protein scaffold","volume":"5","author":"Desmet","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.coviro.2017.03.009_bib0355","first-page":"255","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"7","author":"Crotty","year":"2001","journal-title":"Nat. Med."}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716301547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716301547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T23:04:34Z","timestamp":1658099074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625716301547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":71,"alternative-id":["S1879625716301547"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2017.03.009","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-acting antivirals and host-targeting strategies to combat enterovirus infections","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2017.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}